Highlights
Background
Differentiated thyroid carcinoma represents the most common malignancy of the endocrine system, with incidence rates steadily increasing globally over the past several decades. While DTC generally carries an excellent prognosis—with five-year survival rates exceeding 95% for most subtypes—the psychological burden experienced by patients throughout their treatment journey has emerged as a significant clinical concern. Unlike malignancies with more guarded prognoses, thyroid cancer patients often face unique challenges related to long-term hormone management, surgical alterations to the neck region, and radioactive iodine therapy protocols that may impact quality of life in ways not fully captured by traditional oncological endpoints.
